acquired
Stage
3
Investors
About
DJS Antibodies was a biotechnology company based in Oxford, UK, specializing in the discovery and development of antibody-based therapeutics. They focused on targeting G protein-coupled receptors (GPCRs) for autoimmune and inflammatory diseases, and were acquired by AbbVie in 2022.
Explore DJS Antibodies's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.